These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 17245806

  • 1. A [meso-tetrakis(4-sulfonatophenyl)porphyrinato]zinc(ii) complex as an oral therapeutic for the treatment of type 2 diabetic KKA(y) mice.
    Saha TK, Yoshikawa Y, Sakurai H.
    ChemMedChem; 2007 Feb; 2(2):218-25. PubMed ID: 17245806
    [Abstract] [Full Text] [Related]

  • 2. A Zinc(II)/poly(gamma-glutamic acid) complex as an oral therapeutic for the treatment of type-2 diabetic KKAy mice.
    Karmaker S, Saha TK, Yoshikawa Y, Sakurai H.
    Macromol Biosci; 2009 Mar 10; 9(3):279-86. PubMed ID: 18989849
    [Abstract] [Full Text] [Related]

  • 3. A new type of orally active anti-diabetic Zn(II)-dithiocarbamate complex.
    Yoshikawa Y, Adachi Y, Sakurai H.
    Life Sci; 2007 Jan 30; 80(8):759-66. PubMed ID: 17137606
    [Abstract] [Full Text] [Related]

  • 4. Oral administration of a zinc complex improves type 2 diabetes and metabolic syndromes.
    Adachi Y, Yoshida J, Kodera Y, Kiss T, Jakusch T, Enyedy EA, Yoshikawa Y, Sakurai H.
    Biochem Biophys Res Commun; 2006 Dec 08; 351(1):165-70. PubMed ID: 17052688
    [Abstract] [Full Text] [Related]

  • 5. The pharmacology of the insulinomimetic effect of zinc complexes.
    Sakurai H, Adachi Y.
    Biometals; 2005 Aug 08; 18(4):319-23. PubMed ID: 16158223
    [Abstract] [Full Text] [Related]

  • 6. Improvement of hyperglycaemia and metabolic syndromes in type 2 diabetic KKAy mice by oral treatment with [meso-tetrakis(4-sulfonatophenyl) porphyrinato]oxovanadium(IV)(4-) complex.
    Saha TK, Yoshikawa Y, Sakurai H.
    J Pharm Pharmacol; 2007 Mar 08; 59(3):437-44. PubMed ID: 17331348
    [Abstract] [Full Text] [Related]

  • 7. A family of insulinomimetic zinc(II) complexes of amino ligands with Zn(Nn) (n=3 and 4) coordination modes.
    Yoshikawa Y, Kondo M, Sakurai H, Kojima Y.
    J Inorg Biochem; 2005 Jul 08; 99(7):1497-503. PubMed ID: 15921760
    [Abstract] [Full Text] [Related]

  • 8. A new insulin-mimetic bis(allixinato)zinc(II) complex: structure-activity relationship of zinc(II) complexes.
    Adachi Y, Yoshida J, Kodera Y, Kato A, Yoshikawa Y, Kojima Y, Sakurai H.
    J Biol Inorg Chem; 2004 Oct 08; 9(7):885-93. PubMed ID: 15378407
    [Abstract] [Full Text] [Related]

  • 9. Syntheses of vanadyl and zinc(II) complexes of 1-hydroxy-4,5,6-substituted 2(1H)-pyrimidinones and their insulin-mimetic activities.
    Yamaguchi M, Wakasugi K, Saito R, Adachi Y, Yoshikawa Y, Sakurai H, Katoh A.
    J Inorg Biochem; 2006 Feb 08; 100(2):260-9. PubMed ID: 16387366
    [Abstract] [Full Text] [Related]

  • 10. Amelioration of hyperglycemia and metabolic syndromes in type 2 diabetic KKA(y) mice by poly(gamma-glutamic acid)oxovanadium(IV) complex.
    Karmaker S, Saha TK, Yoshikawa Y, Sakurai H.
    ChemMedChem; 2007 Nov 08; 2(11):1607-12. PubMed ID: 17768733
    [Abstract] [Full Text] [Related]

  • 11. Improvement of diabetes, obesity and hypertension in type 2 diabetic KKAy mice by bis(allixinato)oxovanadium(IV) complex.
    Adachi Y, Yoshikawa Y, Yoshida J, Kodera Y, Katoh A, Takada J, Sakurai H.
    Biochem Biophys Res Commun; 2006 Jul 07; 345(3):945-50. PubMed ID: 16707105
    [Abstract] [Full Text] [Related]

  • 12. Insulinomimetic bis(maltolato)zinc(II) complex: blood glucose normalizing effect in KK-A(y) mice with type 2 diabetes mellitus.
    Yoshikawa Y, Ueda E, Miyake H, Sakurai H, Kojima Y.
    Biochem Biophys Res Commun; 2001 Mar 07; 281(5):1190-3. PubMed ID: 11243860
    [Abstract] [Full Text] [Related]

  • 13. Development of new insulinomimetic zinc(II) picolinate complexes with a Zn(N2O2) coordination mode: structure characterization, in vitro, and in vivo studies.
    Yoshikawa Y, Ueda E, Kawabe K, Miyake H, Takino T, Sakurai H, Kojima Y.
    J Biol Inorg Chem; 2002 Jan 07; 7(1-2):68-73. PubMed ID: 11862542
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of insulin-mimetic activities of vanadyl and zinc(II) complexes from the viewpoint of heterocyclic bidentate ligands.
    Katoh A, Matsumura Y, Yoshikawa Y, Yasui H, Sakurai H.
    J Inorg Biochem; 2009 Apr 07; 103(4):567-74. PubMed ID: 19162327
    [Abstract] [Full Text] [Related]

  • 15. A novel drug delivery system for type 1 diabetes: insulin-mimetic vanadyl-poly(gamma-glutamic acid) complex.
    Karmaker S, Saha TK, Yoshikawa Y, Yasui H, Sakurai H.
    J Inorg Biochem; 2006 Sep 07; 100(9):1535-46. PubMed ID: 16824605
    [Abstract] [Full Text] [Related]

  • 16. Blood glucose lowering and toxicological effects of zinc (II) complexes with maltol, threonine, and picolinic acid.
    Kojima Y, Yoshikawa Y, Ueda E, Kondo M, Takahashi S, Matsukura T, Sakurai H, Hiroi T, Imaoka S, Funae Y.
    Res Commun Mol Pathol Pharmacol; 2002 Sep 07; 112(1-4):91-104. PubMed ID: 15080500
    [Abstract] [Full Text] [Related]

  • 17. Oral administration of Bis(aspirinato)zinc(II) complex ameliorates hyperglycemia and metabolic syndrome-like disorders in spontaneously diabetic KK-A(y) mice: structure-activity relationship on zinc-salicylate complexes.
    Yoshikawa Y, Adachi Y, Yasui H, Hattori M, Sakurai H.
    Chem Pharm Bull (Tokyo); 2011 Sep 07; 59(8):972-7. PubMed ID: 21804241
    [Abstract] [Full Text] [Related]

  • 18. Antidiabetic activity of the orally effective vanadyl-poly (gamma-glutamic acid) complex in streptozotocin(STZ)-induced type 1 diabetic mice.
    Karmaker S, Saha TK, Sakurai H.
    J Biomater Appl; 2008 Mar 07; 22(5):449-64. PubMed ID: 17494957
    [Abstract] [Full Text] [Related]

  • 19. Pharmacological and pharmacokinetic studies of anti-diabetic tropolonato-Zn(II) complexes with Zn(S(2)O(2)) coordination mode.
    Murakami H, Yasui H, Yoshikawa Y.
    Chem Pharm Bull (Tokyo); 2012 Mar 07; 60(9):1096-104. PubMed ID: 22976316
    [Abstract] [Full Text] [Related]

  • 20. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
    Wenying Y, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, Shah S, Shestakova M, Ligthelm R, Valensi P, IMPROVE Study Group Expert Panel.
    Curr Med Res Opin; 2009 Nov 07; 25(11):2643-54. PubMed ID: 19751116
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.